P1.01 TREATMENT OF ADVANCED DISEASE – NSCLC
- Immunotherapy
- EGFR MT
- ALK
- Clinical Care of Lung Cancer
- Chemotherapy Developments
- Meta Analyses and Trial Conduct
- EGFR WT, Angiogenesis, OMD
- New Targets
- Trials in Progress

P1.02 TREATMENT OF LOCALIZED DISEASE – NSCLC
- Quality/Prognosis/Survival
- Surgery
- Chemotherapy in Early Stage Disease
- Radiation

P1.03 TREATMENT OF LOCOREGIONAL DISEASE – NSCLC
- Surgery
- Chemoradiation
- Radiation
- Other

P1.04 BIOLOGY, PATHOLOGY, AND MOLECULAR TESTING
- KRAS
- Pathology
- Biology
- Preclinical Therapy

P1.05 PREVENTION AND TOBACCO CONTROL
- Prevention and Tobacco Control

P1.06 SCREENING AND EARLY DETECTION
- CT Screening Programs and Imaging
- Biomarkers
- Risk, Health Care Delivery, Miscellaneous, P1.06-013 – P1.06-020
- Case Reports and Series
- Diagnostic Workup P1.06-021 – P1.06-026
- Prognostic Markers P1.06-027 – P1.06-029

P1.07 SMALL CELL LUNG CANCER
- Biology P1.07-001 – P1.07-003
- Extensive Disease P1.07-004 – P1.07-008
- Limited Disease P1.07-009 – P1.07-012
- Prognosis, Epidemiology and Other P1.07-013 – P1.07-016

P1.08 THYMOMA, MESOTHELIOMA AND OTHER THORACIC MALIGNANCIES
- Mesothelioma P1.08-001 – P1.08-018
- Other Thoracic Malignancies P1.08-019 – P1.08-032
- Thymoma P1.08-033 – P1.08-039

P1.09 NURSING AND ALLIED PROFESSIONALS
- No Posters on Monday, September 7

P1.10 ADVOCACY
- Advocacy P1.10-001 – P1.10-008

P1.11 PALLIATIVE AND SUPPORTIVE CARE
- Palliative and Supportive Care P1.11-001 – P1.11-013

P1.12 COMMUNITY PRACTICE
- Community Practice P1.12-001 – P1.12-011
Monday, September 7, 2015

Poster Setup Time: 08:30 – 09:30
Poster Take Down Time: 16:45 – 18:30
(Posters not taken down by 18:30 will be discarded by management)

PRESENTING AUTHOR STAND BY TIME

Time in which Poster Presenters remains at his/her poster board and is available to discuss their research personally with interested delegates.
09:45 – 10:45 and 15:45 – 16:45 (Networking Breaks)

P1.01 TREATMENT OF ADVANCED DISEASE NSCLC

P1.01 TREATMENT OF ADVANCED DISEASE – NSCLC - IMMUNOTHERAPY

P1.01-001: Pembrolizumab for Advanced NSCLC: Patterns of Response and Progression
Jenny H. J. Lee, Australia

P1.01-002: Response Evaluation and Predictors in NSCLC During Treatment with AntiPD-L1
Alessandra Bearz, Italy

P1.01-003: Co-Expression of Programmed Death Ligand-1 (PD-L1) and CD3 in Patients with EGFR Mutant NSCLC Treated with EGFR Tyrosine Kinase Inhibitors (TKI)
Ross Soo, Singapore

P1.01 TREATMENT OF ADVANCED DISEASE - NSCLC – EGFR MT

P1.01-004: Updated Results and Efficacy Analysis According to EGFR Mutation Subtypes for Gefitinib plus Carboplatin and S-1 of the Phase II Trial
Akihiro Tamiya, Japan

P1.01-005: Early versus Late Brain Metastases in Wild Type and Mutation Positive EGFR Patients
Cheryl Ho, Canada

P1.01-006: Targeted Drug Selection for Advanced NSCLC Treatment
Jun Ni, China

P1.01-007: Treatment with EGFR-TKIs in Non Small Cell Lung Cancer Patients. The Impact of EGFR Mutations
Teresa Garcia Manrique, Spain

P1.01-008: Second Line Erlotinib for NSCLC Patients with EGFR Mutation: Our Experience
Simonida Crvenkova, Macedonia
P1.01-009: **Combination of Angiogenesis Inhibitor and EGFR-TKIs in Advanced NSCLC Patients Who Developed Acquired Resistance**
Xia Song, China

P1.01-010: **Development of Skin Rash within the First Week Is a Potential Surrogate Marker of Effect in Afatinib for EGFR Mutant NSCLC**
Kenichiro Kudo, Japan

P1.01-011: **Response to Erlotinib in Metastatic Lung Adenocarcinoma with a Rare Double Epidermal Growth Factor Receptor (EGFR) Mutation**
Syed H. R. Jafri, USA

P1.01-012: **Kinase Domain Mutation Positive Lung Cancers Are Sensitive to Intrapeural Perfusion with Hyperthermic Chemotherapy (IPHC) Complete Treatment**
Lei Yu, China

P1.01-013: **EGFR Mutations and Targeted Treatment Reverse the Bad Prognosis of Stage IV NSCLC Associated to Liver Metastasis**
Ignacio Gil-Bazo, Spain

P1.01-014: **Long Term Clinical Benefit of EGFR wt in Advanced NSCLC Patients Treated for Long Time with Salvage Erlotinib. A Retrospective Analysis**
Athanasios Kotsakis, Greece

P1.01-015: **Clinical-Pathological and Survival Analysis of Patients with Advanced NSCLC and EGFR Mutation Treated With a Drug Therapy Anti-T790M**
Jesús Corral, Spain

P1.01-016: **Treatment Outcomes among Elderly Lung Cancer Patients > 65 Years following Clinical Use of EGFR Tyrosine Kinase Inhibitor**
Wan-Teck Lim, Singapore

P1.01-017: **Two Cases of NSCLC with EGFR Exon 20 Insertions with Major Clinical Response to Cetuximab-Containing Therapies**
Chad M. Vanderbilt, USA

**P1.01 TREATMENT OF ADVANCED DISEASE - NSCLC – ALK**

P1.01-018: **Response Rate and Outcomes in Crizotinib Treated Advanced ALK-Positive NSCLC Patients**
Keith L Davis, USA

P1.01-019: **Czech Experience with Crizotinib in the Personalized Treatment of NSCLC**
Vitezslav Kolek, Czech Republic

P1.01-020: **Symptoms of Bone and Liver Metastases in Patients with ALK+ Non-Small Cell Lung Cancer (NSCLC)**
Anand Dalal, USA
P1.01-021: Crizotinib Efficacy in ALK-Positive Advanced NSCLC Chinese Patients
Liyan Jiang, China

P1.01-022: Radiologic Features of Advanced ALK-Rearranged Lung Cancer
Kakeru Hisakane, Japan

P1.01-023: Discrepancy of ALK Status in Lung Adenocarcinoma Subtypes According to the IALSC/ATS/ERS Classification in Chinese Patients
Shun Lu, China

P1.01 TREATMENT OF ADVANCED DISEASE – NSCLC – CLINICAL CARE OF LUNG CANCER

P1.01-024: Case Report of a Patient with Non-Small Cell Cancer Treated in Two Consecutive Randomized Clinical Trials. Safety of Imaging Procedures
Ewa Chmielowska, Poland

P1.01-025: Radical Resection for Supraclavicular Lymph Node Metastasis (N3-Stage IIIIB) Adenocarcinoma of the Lung
Jun Zhang, China

P1.01-026: Post-Treatment Effects of Lung Cancer on Spinal Fracture
Malcolm O. Tagbarha, Nigeria

P1.01-027: Prognostic Impact of Cytological Fluid Tumor Markers in Non-Small Cell Lung Cancer
Arthur Cho, South Korea

P1.01-028: Pathological Characteristics of Lung Cancer Patients in Colombian Coffee Zone
Paula Londno, Colombia

P1.01-029: Dutch Radiotherapy Lung Audit: Results of 2014
Jose Belderbos, Netherlands

P1.01-030: Curable Bulky T4 Right Lower Lobe Tumours Invading Diaphragm and Liver: A Distinct Entity?
Noelle O’Rourke, United Kingdom

P1.01-031: Feasibility of Median Sternotomy Approach for Locally Advanced Lung Cancer
Hiroki Sato, Japan

P1.01-032: Surgical Resection for Lung Adenocarcinoma after Afatinib Treatment
Hirofumi Suzuki, Japan

P1.01-033: Multiple Organ Metastasis Could Be Identified as Poor Prognostic Factors for NSCLC
Zhenrong Zhang, China
P1.01-034: Is There A "Physician Effect" in Medical Oncology?  
Paul Wheatley-Price, Canada

P1.01-035: Clinico-Epidemiological Features and Survival Outcome in Patients with NSCLC: Ain Shams Clinical Oncology Department 5-Year Data  
Ahmed A. Nagy, Egypt

P1.01-036: RFA for Palliative Treatment of NSCLC Rib Painful Metastasis: Experience in 12 Patients  
Hu Mu, China

P1.01-037: Successful Treatment of Non-Small Cell Lung Cancer with Erlotinib throughout Pregnancy  
Claire Verschraegen, USA

P1.01-038: Endosonographic vs Surgical Staging for Mediastinal Nodal Staging of Lung Cancer: A Systematic Review  
Prakash Balakrishnan, New Zealand

P1.01-039: Lung Cancer in Kidney Transplant Recipients: A Case-Control Retrospective Study of 30 Patients  
Séverine Fraboulet, France

P1.01-040: Determining Completeness of Case Ascertainment to the Victorian Lung Cancer Registry: A Quantitative Case Finding Audit  
Rob Stirling, Australia

P1.01-041: Prognostic Significance of CT Emphysema Score in Patients with Advanced Squamous Cell Carcinoma of the Lung  
Young Saing Kim, South Korea

P1.01 TREATMENT OF ADVANCED DISEASE – NSCLC - CHEMOTHERAPY DEVELOPMENTS

P1.01-042: Maintenance Therapy with Pemetrexed after Induction Therapy with Pemetrexed plus Cisplatin for Advanced Pulmonary Adenocarcinoma  
Ho-Kee Yum, South Korea

P1.01-043: Prognostic Factors in the First-Line Chemotherapy of Advanced Non-Squamous Non-Small Cell Lung Cancer Patients with Performance Status 2  
Shinobu Hosokawa, Japan

P1.01-044: Cost-Effectiveness of Chemotherapy Based on the Tumor Genetic Profile in Elderly Patients with Advanced Non-Small-Cell Lung Cancer  
Silvia Novello, Italy

P1.01-045: Drug Fever After Cancer Chemotherapy Is Most Commonly Observed on Post-Treatment Days 3-4  
Minoru Fukuda, Japan
P1.01-046: Characteristics of Complete Remission Cases in Advanced Non-Small Cell Lung Cancer  
Takuya Aoki, Japan

P1.01-047: Pemetrexed in Treating Advanced NSCLC  
Luis Mas, Peru

P1.01-048: Cost-Effectiveness of Pemetrexed for Advanced Non-Squamous Non-Small Cell Lung Cancer (nsNSCLC) in Patients Treated in a Spanish Institution  
Xabier Mielgo Rubio, Spain

P1.01-049: Feasibility of Cisplatin plus Etoposide for Non-Small Cell Lung Cancer Associated with Interstitial Lung Disease on Chest Computed Tomography  
Masafumi Yamaguchi, Japan

P1.01-050: Clinical Features of Non-Squamous Non-Small-Cell Lung Cancer Patients Treated with Long-Term Pemetrexed  
Kenichiro Hirai, Japan

P1.01-051: Efficiency of Nab-Paclitaxel as a Late Phase Chemotherapy for NSCLC  
Mitsunori Higuchi, Japan

P1.01-052: Retreatment with Platinum-Based Regimen for Patients with Metastatic NSCLC Is a Reasonable Therapy  
Rachel L. Mitchell, USA

P1.01-053: Thiol - Disulfide Ratio (TDR) in Blood as a Predictive in Vitro Test for Individualized Targeted Therapy Choice in Patients with Advanced NSCLC  
Oleksandr O. Obodnikov, Ukraine

P1.01-054: To Analyse the Efficacy and Toxicity Profile of Continuation Maintenance Pemetrexed in Advanced NSCLC: An Indian Data  
Ullas Batra, India

P1.01-055: Prognostic Impact of KRAS Mutational Status in Patients with Advanced Lung Adenocarcinoma Receiving First-Line Cytotoxic Chemotherapy  
Arpita Desai, USA

P1.01-056: A Prospective Audit on Toxicity for Platinum-Based Chemotherapy in Stage IIB/IV Non-Small Cell Lung Cancer (NSCLC): A West of Scotland Analysis  
Clinton W. Ali, United Kingdom

P1.01-057: Gemcitabine plus Platinum versus Other Platinum Doublets in Squamous NSCLC  
Caicun Zhou, China
<table>
<thead>
<tr>
<th>Presentation</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1.01-058:</td>
<td>Impact of Low-Grade Toxicity on Lung Cancer Patient Willingness to Undergo Treatment with Novel Agents</td>
<td>Emily H. Castellanos, USA</td>
</tr>
<tr>
<td>P1.01-059:</td>
<td>Steps to Improve NSCLC Patient Outcomes Utilizing Mobile Apps - Survey Findings</td>
<td>Corey J. Langer, USA</td>
</tr>
<tr>
<td>P1.01-060:</td>
<td>Value Based Health Care Analysis for Lung Cancer Patients</td>
<td>Ben Van Den Borne, Netherlands</td>
</tr>
<tr>
<td>P1.01-061:</td>
<td>The Chicago Thoracic Oncology Database Consortium: A Multi-Site Database Initiative</td>
<td>Brian M. Won, USA</td>
</tr>
<tr>
<td><strong>P1.01</strong> TREATMENT OF ADVANCED DISEASE – NSCLC - EGFT WT, ANGIOGENESIS, OMD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>P1.01-062:</td>
<td>Rash as a Marker for the Efficacy of Necitumumab in the SQUIRE Study</td>
<td>Philip Bonomi, USA</td>
</tr>
<tr>
<td>P1.01-063:</td>
<td>Efficacy and Safety of Erlotinib in Squamous Cell Lung Cancer</td>
<td>Marko Jakopovic, Croatia</td>
</tr>
<tr>
<td>P1.01-064:</td>
<td>A Phase II Study of Gemcitabine-Cisplatin plus Necitumumab for Stage IV Sq-NSCLC</td>
<td>Jesús Corral, Spain</td>
</tr>
<tr>
<td>P1.01-065:</td>
<td>Bevacizumab Combined with Chemotherapy in the Treatment of Advanced NSCLC Patients</td>
<td>Zhe Liu, China</td>
</tr>
<tr>
<td>P1.01-066:</td>
<td>Maintenance Bevacizumab after Chemotherapy with Bevacizumab in First Line Treatment of Lung Cancer. A Single Institution Experience</td>
<td>Malika Gamaz Bensaou, Algeria</td>
</tr>
<tr>
<td>P1.01-067:</td>
<td>Epidermal Growth Factor Receptor Gene Amplification in Patients with Advanced-Stage NSCLC</td>
<td>Ondrej Fiala, Czech Republic</td>
</tr>
<tr>
<td>P1.01-068:</td>
<td>Randomized Trial of Maintenance Chemotherapy Versus SBRT plus Maintenance Chemotherapy for Advanced NSCLC - Feasibility and Early Outcomes</td>
<td>Zabi Wardak, USA</td>
</tr>
<tr>
<td>P1.01-069:</td>
<td>Reasons for Discontinuation of Treatment with Bevacizumab in Patients with Non-Progressing NSCLC - Retrospective Study</td>
<td>Peter Berzinec, Slovakia</td>
</tr>
</tbody>
</table>
P1.01-070: KRAS Mutations: Does It Mean No Erlotinib?
Margarida Dias, Portugal

P1.01-071: Long-Term Tolerability Among IRESSA Clinical Access Program (ICAP) Participants in the United States (US)
Fred R. Hirsch, USA

P1.01 TREATMENT OF ADVANCED DISEASE – NSCLC - NEW TARGETS

P1.01-072: Targeted Delivery of a Synthetic microRNA-Based Mimic to Treat Thoracic Cancers
Glen Reid, Australia

P1.01-073: MET and Invasive Function in NSCLC
Tamara Mirzapioazova, USA

P1.01 TREATMENT OF ADVANCED DISEASE – NSCLC - TRIALS IN PROGRESS

P1.01-074: Phase III Study of WBRT with or without Erlotinib for Brain Metastasis NSCLC
Zhen-zhou Yang, China

P1.01-075: Phase III, Randomized, Double-Blind Trial of Bavituximab Plus Docetaxel in Previously Treated Stage IIIb/IV Non-Squamous NSCLC (SUNRISE)
David R. Spigel, USA

P1.01-076: TIGER-1: A Phase 2/3 Study of First Line Rociletinib or Erlotinib in EGFR-Mutant NSCLC
Ross Camidge, USA

P1.01-077: First-Line Nivolumab + Nab-Paclitaxel + Carboplatin (C) in Advanced NSCLC
Karen Kelly, USA

P1.01-078: Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1-Strong-Positive NSCLC
Julie R. Brahmer, USA

P1.01-079: Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone as First-Line Therapy for NSCLC
Shirish Gadgeel, USA

P1.01-080: Treatment Rationale and Study Design for the Phase 3 JUNIPER Study: Abemaciclib vs Erlotinib in Patients with Stage IV NSCLC and KRAS Mutation
Jonathan W. Goldman, USA

P1.01-081: Patritumab Plus Erlotinib in EGFR Wild-Type Advanced Non-Small Cell Lung Cancer: A 2-Part Phase 3 Study (HER3-Lung)
Wallace L. Akerley, USA
P1.01-082: A Phase III Study of MEDI4736 (M) an Anti-PD-L1 Antibody ± Tremelimumab (T), vs Standard of Care (SoC), in Patients with Advanced NSCLC (ARCTIC)
David Planchard, France

P1.01-083: Phase 2 Study of MEDI4736 in Patients with PD-L1+ Locally Advanced or Metastatic Stage IIIb-IV NSCLC Treated with ≥ 2 Prior Regimens (ATLANTIC)
Marina C. Garassino, Italy

P1.01-084: A Phase 2 Study of TH-4000 in Patients with EGFR Mutant, T790M-Negative, Advanced NSCLC Progressing on an EGFR TKI
Stephen V. Liu, USA

P1.01-085: A Multicenter Phase 1B Study of Ceritinib plus Nivolumab in Patients with ALK+ NSCLC
Alice Shaw, USA

P1.01-086: TIGER-3: A Phase 3 Open-Label, Randomized Study of Rociletinib vs Chemotherapy in NSCLC
James Chih-Hsin Yang, Taiwan

P1.01-087: A Phase I Study of Chloroquine with Carboplatin and Gemcitabine in Advanced Solid Tumors and NSCLC
Nagla Abdel Karim, USA

P1.02 TREATMENT OF LOCALIZED DISEASE - NSCLC

P1.02 TREATMENT OF LOCALIZED DISEASE – NSCLC – QUALITY/PROGNOSIS/SURVIVAL

P1.02-001: Predictive Factors of Distant and Local Recurrence in Patients with Surgically Resected Stage 1 NSCLC
Shinjiro Mizuguchi, Japan

P1.02-002: Interstitial Lung Disease (ILD) Associated Cancer Genesis Is Noble Predictor for Patients with Non-Small Cell Lung Cancer and ILD
Ryo Miyata, Japan

P1.02-003: Accuracy of Clinical and Pathologic Staging of Non-Small Cell Lung Cancer in a Residency Education Program
Mariam J. Almarashda, USA

P1.02-004: Accurate Assessment of Vessel Invasion Using D2-40 and Victoria Blue Predicts Recurrence in Patients with Pathological Stage I NSCLC
Satoshi Okada, Japan

P1.02-005: Impact of Postoperative Complications on Cancer Recurrence following Lung Cancer Surgery
Takashi Nojiri, Japan
P1.02-006: Visceral Pleural Invasion Was Common in Larger (> 2 cm) Ground Glass Nodules, but Showed No Aggressive Prognostic Impact
Lilan Zhao, China

P1.02-007: The Histologic Subtype of Lung Adenocarcinoma Should Not Deter Sublobar Resection for Patients with Clinical Stage IA Lung Cancer
Mohamed Kamel, USA

P1.02-008: Diagnostic Molecular Testing in Multiple Lung Cancers
Jarushka Naidoo, USA

P1.02-009: Prognostic Value of New IASLC/ATS/RES Lung Adenocarcinoma Classification on Dominate Tumor in Synchronous Multiple Primary Adenocarcinomas
Chien-Sheng Huang, Taiwan

P1.02-010: What Is the Difference between Lung Cancer and Infectious Lung Disease in Predicted Postoperative Pulmonary Function after Pneumonectomy?
Takayuki Nakagawa, Japan

P1.02-011: The Discordance of Two Major Diagnostic Criteria for Chronic Obstructive Pulmonary Disease Affects Lung Cancer Prognosis after Resection
Masaya Yotsukura, Japan

P1.02-012: Study for Prognostic Impact of Tumor Volume Instead of Tumor Size for T Staging in NSCLCancer
Doosang Kim, South Korea

P1.02-013: The New Interventional Technique by Photodynamic Therapy Using Composite-Type Optical Fiberscope of 1.0 mm in Diameter
Jitsuo Usuda, Japan

P1.02-014: Predictive Factors of Postoperative Acute Exacerbation of Interstitial Pneumonia for Patients with Lung Cancer
Haruhiro Yukiue, Japan

P1.02-015: Pathological Variables in Resected NSCLC Tumours: Predictors of Survival?
Haider Al-Najjar, United Kingdom

P1.02  TREATMENT OF LOCALIZED DISEASE – NSCLC – SURGERY

Toshiki Takemoto, Japan

P1.02-017: Complications after Lobectomy or Segmentectomy for cT1aN0M0 Non-Small Cell Lung Cancer
Takashi Ohtsuka, Japan
P1.02-018: Needleoscopic Lobectomy and Segmentectomy for Primary Lung Cancer: Less Invasive Surgery Using Fine Scope and Forceps
Michihiko Tajiri, Japan

P1.02-019: Effectiveness of Touch Cytology on the Staple Line in the Assessment of Resection Margins for Pulmonary Malignant Tumors
Rie Nakahara, Japan

P1.02-020: Physiological Assessment in Thoracic Surgery for High Risk Patients with Lung Cancer; How Do International Guidelines Compare?
Haider Al-Najjar, United Kingdom

P1.02-021: The Feasibility of Fluorescence Image-Guided Surgery for Pulmonary Nodules
Hyun Koo Kim, South Korea

P1.02-022: Sleeve Lobectomy Is a Safe and Effective Oncologic Procedure: A Single Center Experience over Three Decades
Luis Carlos Silva Corten, Belgium

P1.02-023: The Role of Selective EBUS-TBNA Mediastinal Sampling in Early Lung Cancer
Rajaram Burrah, Australia

P1.02-024: Conditional Survival after Surgical Treatment of Non-Small Cell Lung Cancer
Takayuki Fukui, Japan

P1.02-025: Complete VATS Resection and Reconstruction of Carina and Trachea for Malignant or Benign Disease
Jianxing He, China

P1.02-026: For NSCLC with T3 (Central) Disease, Sleeve Lobectomy or Pneumonectomy?
Qianli Ma, China

P1.02-027: Thoracoscopic Segmentectomy of Pulmonary Nodules after Computed Tomography-Assisted Bronchoscopic Metallic Coil Marking
Takanori Miyoshi, Japan

P1.02-028: Surgical Resection for Sarcomatoid Carcinoma of the Lung
Tarek Kilani, Tunisia

P1.02-029: Long and Short-Term Predictors of Outcome in Elderly Patients (≥ 75 Years) Undergoing Lobectomy for Stage I Non-Small Cell Lung Cancer
Takashi Eguchi, USA

P1.02-030: Effectiveness of Extended Bilateral Superior Mediastinal Lymph Node Dissection Through a Median Sternotomy in Patients with Left NSCLC
Toshiya Yokota, Japan
**P1.02-031:** Wedge Resection for NSCLC: Does Minimally Invasive Surgery Warrant the Maximum Advantage?  
Pietro Bertoglio, Italy

**P1.02** TREATMENT OF LOCALIZED DISEASE – NSCLC – CHEMOTHERAPY IN EARLY STAGE DISEASE

**P1.02-032:** Randomized Feasibility Study of S-1 for Adjuvant Chemotherapy in Completely-Resected Stage IA Non-Small-Cell Lung Cancer (SLCG 0701)  
Norihiro Okumura, Japan

**P1.02-033:** Pemetrexed plus Platinum as Adjuvant Therapy in Patients with Resected Lung Adenocarcinoma and Exploratory Biomarkers Analysis  
Bing Xia, China

**P1.02** TREATMENT OF LOCALIZED DISEASE – NSCLC – RADIATION

**P1.02-034:** Lung v5 Does Not Predict for Lung Toxicity after Fixed-Beam Intensity Modulated Radiotherapy (IMRT)  
Corinne Faivre-Finn, United Kingdom

**P1.02-035:** Radiographic Changes in Lung of Patients Treated with Stereotactic Ablative Body Radiation Therapy and the Dosimetric Correlations  
Fen Wang, USA

**P1.02-036:** Peripheral Blood Immunophenotype Changes Following Thoracic Stereotactic Ablative Radiotherapy  
Megan E. Daly, USA

**P1.02-037:** Thoracic Radiation-Induced Pleural Effusion and Risk Factors in Patients with Lung Cancer  
Feng-Ming (Spring) Kong, USA

**P1.02-038:** A Comparison of Stereotactic Body Radiation Therapy vs. No Treatment for Patients with Early-Stage Non-Small Cell Lung Cancer  
Stefan S. Jeppesen, Denmark

**P1.02-039:** Stereotactic Radiotherapy as Salvage Treatment after Stereotactic Radiotherapy or after Operated Non-Small-Cell Lung Cancer  
Charlotte Kristiansen, Denmark

**P1.03** TREATMENT OF LOCOREGIONAL DISEASE - NSCLC

**P1.03** TREATMENT OF LOCOREGIONAL DISEASE – NSCLC - SURGERY

**P1.03-001:** Survival of the NSCLC Patients with Clinical Stage IIIA Disease with N2 Involvement: Case-Control Study with Emphasis on Treatment Modality  
Ilkka Ilonen, Finland
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1.03-002</td>
<td>Surgery in Subclassified Stage IIIA-N2 Lung Cancer Improves Survival</td>
<td>Hans-Stefan Hofmann, Germany</td>
</tr>
<tr>
<td>P1.03-003</td>
<td>A Clinicopathological Study of Resected Small-Sized Non-Small Cell Lung Cancer 2 cm or Less in Diameter with N2 Lymph Node Metastasis</td>
<td>Yasufumi Kato, Japan</td>
</tr>
<tr>
<td>P1.03-004</td>
<td>Occult Primary Non-Small Cell Lung Cancer with Mediastinal Lymph Node Involvement</td>
<td>Andreas Rimner, USA</td>
</tr>
<tr>
<td>P1.03-005</td>
<td>Bilobectomy for Lung Cancer: Postoperative Results, and Long-Term Outcomes</td>
<td>M Rahouma, USA</td>
</tr>
<tr>
<td>P1.03-006</td>
<td>Survival Analysis of 121 Cases of Stage III A (N2) Non-Small Cell Lung Cancer Treated with Surgery Resection</td>
<td>Hao Fu, China</td>
</tr>
<tr>
<td>P1.03-007</td>
<td>Prognosis of Microscopic Residual Disease (R1) at Different Resection Margins and Efficacy of Adjuvant Therapy</td>
<td>Masato Chiba, Japan</td>
</tr>
</tbody>
</table>

**P1.03 TREATMENT OF LOCOREGIONAL DISEASE – NSCLC - CHEMORADIATION**

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1.03-008</td>
<td>Weekly Carboplatin/Gemcitabine + Concurrent Thoracic RT Followed by Consolidation Carboplatin/Gemcitabine for Inoperable Stage III NSCLC</td>
<td>Manuel Domine, Spain</td>
</tr>
<tr>
<td>P1.03-009</td>
<td>Integration of Chemoradiotherapy in a Single Facility: Impact on Outcomes for Locally Advanced Non-Small Cell Lung Cancer</td>
<td>Roy H. Decker, USA</td>
</tr>
<tr>
<td>P1.03-010</td>
<td>Adjuvant Chemotherapy plus Radiotherapy is Superior to Chemotherapy in Surgically Treated IIIA N2 Non-Small-Cell Lung Cancer</td>
<td>Xiao-Ling Xu, China</td>
</tr>
<tr>
<td>P1.03-011</td>
<td>Standard Pre-Hydration May Compromise Treatment Outcome of CRT with Low-Dose Cisplatin</td>
<td>Else Aalbersberg, Netherlands</td>
</tr>
<tr>
<td>P1.03-012</td>
<td>Combined Effects of SAHA and Cisplatin on Radiation Sensitivity and Cancer Cell Invasion in NSCLC</td>
<td>Shirong Zhang, China</td>
</tr>
<tr>
<td>P1.03-013</td>
<td>Clinical Characteristics and Survival in Stage IIIA NSCLC Patients Treated with Neoadjuvant Chemotherapy and Surgery</td>
<td>Narjjust Duma, USA</td>
</tr>
</tbody>
</table>
P1.03-014: Is Concomitant Chemoradiotherapy Feasible for Patients with NSCLC Stage III A/B?
Femke S. Van Der Meer, Netherlands

P1.03-015: Safety and Effectiveness of Chemo-Radiotherapy with Weekly Nab Paclitaxel plus Carboplatin in Locally Advanced Non-Small Cell Lung Cancer
Toshiyuki Sawa, Japan

P1.03  TREATMENT OF LOCOREGIONAL DISEASE – NSCLC - RADIATION

P1.03-016: Clinical Outcome of Hybrid-Volumetric Arc Therapy (H-VMAT) for Advanced Inoperable Non-Small Cell Lung Cancer (NSCLC)
Oscar S.H. Chan, Hong Kong

P1.03-017: Radiation Dose-Related Lymphopenia as an Outcome Predictor in Stage III NSCLC Patients Treated with Chemoradiation
Nagla Abdel-Karim, USA

P1.03-018: International Patterns of Radiotherapy Practice for Non-Small Cell Lung Cancer
Shalini K. Vinod, Australia

P1.03-019: NTPC-Models for Esophagitis with Dose-Differentiated-Radiotherapy (DART-Bid)
Franz Zehentmayr, Argentina

P1.03-020: IMRT Improves Survival in Locally Advanced NSCLC (LA-NSCLC) Receiving Definitive Radiotherapy: A Population Based Time-Trend Analysis
Luhua (Jingbo) Wang, China

P1.03-021: Lung Damage Quantification on CT Scans Strengthens Radiation-Induced Lung Toxicity Prediction Models
Dirk De Ruysscher, Belgium

P1.03-022: The Effect of Adaptive Planning on Target and Critical Structures During Radiation Treatment for Locally Advanced Lung Cancer
Hale B. Caglar, Turkey

P1.03-023: Changes in Pulmonary Function after Stereotactic Body Radiotherapy and after Surgery for Stage I and II Non-Small-Cell Lung Cancer
Leonie Alberts, Netherlands

P1.03  TREATMENT OF LOCOREGIONAL DISEASE – NSCLC - OTHER

P1.03-024: Comparison of Prognosis Between Patients with Solitary Lung Adenocarcinoma and With Multiple Primary Cancers Including Lung Adenocarcinoma
Sukki Cho, South Korea
P1.03-025: Relation of Visceral Pleura Invasion with Hilar Lymph Node Involvement and Survival in Primary Lung Cancer
Serhan Tanju, Turkey

P1.03-026: Prognostic Value of Pre-Treatment Neutrophil:Lymphocyte Ratio and Platelet:Lymphocyte Ratio in Stage III NSCLC
Tithi Biswas, USA

P1.03-027: Factors Predicting Lymph Node Metastasis in Resected Lung Adenocarcinoma of 2cm or Smaller
Jung-Jyh Hung, Taiwan

P1.03-028: Multicenter Study of the Usefulness of FDG-PET as a Predictor of the Clinicopathological Characteristics and Prognosis of Lung Cancer
Norihiko Ikeda, Japan

P1.03-029: Obesity Is Associated with Long-Term Improved Survival in Definitively Treated Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC)
Vincent K. Lam, USA

P1.03-030: Marital Status Is Strongly Prognostic and Associated with More Favorable Nutritional Status in Locally Advanced Non-Small Cell Lung Cancer
Josephine L. Feliciano, USA

P1.03-031: Concurrent Chemoradiotherapy Using Advanced Radiotherapy Technologies for Inoperable Stage III Non-Small-Cell Lung Cancer
Y C. Li, China

P1.04 BIOLOGY, PATHOLOGY, AND MOLECULAR TESTING

P1.04 BIOLOGY, PATHOLOGY, AND MOLECULAR TESTING - KRAS

P1.04-001: MET/RON Inhibition in KRAS Mutated Non Small Cell Lung Cancer
Sravya Tumuluru, USA

P1.04-002: Protein Signaling Analysis of KRAS Mutant Lung Adenocarcinomas Reveals Variable MAPK and mTOR Pathway Activation
Elisa Baldelli, USA

P1.04-003: Metastatic Site-Specific Variation of KRAS Status in Lung Adenocarcinoma
Balazs Hegedus, Hungary

P1.04-004: Inhibition of Telomerase Activity Suppresses Kras Mutation-Induced Lung Carcinogenesis and Chemoresistance
Bin Zhang, China

P1.04-005: Concurrent EGFR and ALK Mutations in KRAS-Mutant Lung Adenocarcinomas and Their Clinical Behavior
Kevin C. Wood, USA

P1.04-006: Prognostic and Predictive Role of KRAS-Mutations in Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC)
Javier Garde-Noguera, Spain

P1.04-007: KRAS Mutations in Lung Cancer: Prevalence and Outcomes
Margarida Dias, Portugal

P1.04  BIOLOGY, PATHOLOGY, AND MOLECULAR TESTING - PATHOLOGY

P1.04-008: Tissue Hyaluronan and Its Relationship with Angiogenesis Are Indicators of Lung Cancer Malignancy
Maristela P. Rangel, Brazil

P1.04-009: Max Collapse and Fibrosis below 5 cm Predict the Prognosis of pT1 Lepidic Predominant Adenocarcinoma
Masahito Naito, Japan

P1.04-010: Pilot Internet Survey of Interobserver Variability in Pathology Diagnoses of Multiple Tumor Nodules
Wilbur A. Franklin, USA

P1.04-011: Intraoperative Diagnosis of Lymph Node Metastasis Using a Rapid-Immunohistochemical (R-IHC) Staining Method in Non-Small Cell Lung Cancer
Hayato Konno, Japan

P1.04-012: Using Computed Tomography Scans to Assess the Histology of Malignant Pleural Mesothelioma
Samuel Armato, USA

P1.04-013: Clinicopathological Characteristics of Lung Cancer with Combined Pulmonary Fibrosis and Emphysema
Akihiko Yoshizawa, Japan

P1.04-014: Clinicopathologic Significance of Epithelio-Mesenchymal Transition in Human Lung Adenocarcinoma
Toshi Menju, Japan

P1.04-015: Pleomorphic Carcinoma of the Lung: A Clinicopathologic Study of 23 Resected Cases
Dai Sonoda, Japan

P1.04-016: Assessment of the Adequacy of Tissue Diagnosis by EBUS in Relation to the PET Scan and the Operator's Experience
Nagla Abdel Karim, USA
P1.04-017: Pulmonary Lymphoepithelial-Like Carcinoma: A Surveillance, Epidemiology, and End Results Database Analysis
Jiaxi He, China

P1.04-018: The Value of Histopathological Examination for Bronchoscopic Ultrasound Guided Fine-Needle Aspiration in Diagnosis of Lung Cancer Subtypes
Tõnu Vanakesa, Estonia

P1.04-019: A Comparative Study of Micropapillary Pattern and Computed Tomographic Findings in the Patients with Small Lung Adenocarcinoma (≤ 2cm)
Jun-ichi Nitadori, Japan

P1.04-020: Adenocarcinoma Metastatic Gastrointestinal Origin and Lung Squamous Carcinoma Associated with HIV Disease: Case Report
Liliana Fernandez, Colombia

P1.04-021: No MAML2 Gene Alteration Found in Ciliated Muconodular Papillary Tumor of Lung; Genetic Difference from Mucoepidermoid Carcinoma
Noriko Motoi, Japan

P1.04-022: Prognostic Significance of Solid or Micropapillary Component in Pulmonary Invasive Adenocarcinoma Measuring ≤ 3cm
Yuki Matsuoka, Japan

P1.04-023: Primary Adenocarcinoma in the Lung Reclassified - Histological Subtypes and Outcome
Tomas Gudbjartsson, Iceland

P1.04-024: When Bone Starts Growing in the Lung: A Case Series of Pulmonary Ossifications
Paul Van Schil, Belgium

P1.04-025: Lung Cancer Incidence by Histology, Gender, Race/Ethnicity and Socioeconomic Status
Manali I. Patel, USA

P1.04-026: Lung Cancer Patients Who 'Relapse' After Primary Treatment May Have ogy or No Malignancy
Noelle O'Rourke, United Kingdom

P1.04-027: The Expression of Fibroblast Activation Protein (FAP) in Human Lung Cancer Tissues and Its Clinical Significance
Hua Shi, China

P1.04-028: High Vimentin Expression in Micropapillary Component of Lung Adenocarcinomas
Hiroyasu Nakashima, Japan
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1.04-029</td>
<td>Detection of Sputum Cofilin-1 Protein for Diagnosis of Human Non-Small Cell Lung Carcinomas</td>
<td>Vera L. Capelozzi</td>
<td>Brazil</td>
</tr>
<tr>
<td>P1.04-030</td>
<td>Intra-Operative Pleural Lavage Cytology after Thoracotomy for Lung Cancer</td>
<td>Masatoshi Kakihana</td>
<td>Japan</td>
</tr>
<tr>
<td>P1.04-031</td>
<td>The Changing Anatomic Position of Squamous Cell Carcinoma of the Lung - A New Conundrum</td>
<td>Manasa Vulchi</td>
<td>USA</td>
</tr>
<tr>
<td>P1.04-032</td>
<td>Clinical and Pathological Characterization of Long-Term Survivors with Advanced Non-Small Cell Lung Cancer: A Multicenter Experience in Madrid</td>
<td>Maria Eugenia Olmedo</td>
<td>Spain</td>
</tr>
<tr>
<td>P1.04-033</td>
<td>Case of a Patient Who Underwent Right Middle Lobectomy of Lung Adenocarcinoma with Histological Characteristics Similar to Papillary Adenoma</td>
<td>Masato Watanabe</td>
<td>Japan</td>
</tr>
<tr>
<td>P1.04-034</td>
<td>A Case of Fetal Lung Interstitial Tumor (FLIT) in a Neonate</td>
<td>Akiteru Goto</td>
<td>Japan</td>
</tr>
<tr>
<td>P1.04-035</td>
<td>Clinicopathologic and Biological Characteristics of Young Age Non-Small Cell Lung Cancer</td>
<td>Tatsuo Ohira</td>
<td>Japan</td>
</tr>
<tr>
<td>P1.04-036</td>
<td>Primary Pulmonary Melanoma: A Report of Two Cases</td>
<td>Mototsugu Watanabe</td>
<td>Japan</td>
</tr>
<tr>
<td>P1.04-037</td>
<td>Lung and Hypopharyngeal Angiosarcoma (AS) in a Renal Transplant Patient: Case Report</td>
<td>Liliana Fernandez</td>
<td>Colombia</td>
</tr>
<tr>
<td>P1.04-038</td>
<td>Endobronchial Ultrasound Guided Transbronchial Fine Needle Aspiration Cytology (EBUS-TBNA) for Peribronchial Mediastinal Tumor</td>
<td>Mitsutoshi Shiba</td>
<td>Japan</td>
</tr>
<tr>
<td>P1.04-039</td>
<td>Ex-Vivo Artifacts and Histopathological Pitfalls in the Lung</td>
<td>Erik Thunnissen</td>
<td>Netherlands</td>
</tr>
<tr>
<td>P1.04-040</td>
<td>Stage I Adenocarcinoma According to the 2011 IASLC/ATS/ERS: Case Series from Brazil</td>
<td>André Luiz C. Trajano</td>
<td>Brazil</td>
</tr>
<tr>
<td>P1.04-041</td>
<td>Synchronous Lung Cancers, Squamous Cell and Adenocarcinoma Coexistence, Case Report</td>
<td>Nesrin Ocal</td>
<td>Turkey</td>
</tr>
<tr>
<td>Session Code</td>
<td>Title</td>
<td>Authors</td>
<td>Country</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------------------------------------------------------</td>
<td>---------------------------------------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>P1.04-042</td>
<td>Diagnostic Role of Immunocytochemistry in Malignant Pleural Mesothelioma</td>
<td>Nguyen S. Lam</td>
<td>Vietnam</td>
</tr>
<tr>
<td>P1.04-043</td>
<td>Pulmonary Lepidic Adenocarcinoma in a Patient with Prior Diagnosis of Breast Cancer: Case Report</td>
<td>Liliana Fernandez</td>
<td>Colombia</td>
</tr>
<tr>
<td>P1.04-044</td>
<td>Local Diagnostic Practices for Advanced Non-Small-Cell Lung Cancer in Asia-Pacific and Russia: IGNITE Study</td>
<td>Martin Reck</td>
<td>Germany</td>
</tr>
<tr>
<td>P1.04-045</td>
<td>Software Support for Combined Staging of Lung Cancer in CT, Functional MRI and Pathology</td>
<td>Hendrik O. A. Laue</td>
<td>Germany</td>
</tr>
<tr>
<td></td>
<td><strong>P1.04  BIOLOGY, PATHOLOGY, AND MOLECULAR TESTING - BIOLOGY</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P1.04-046</td>
<td>MFN2 Regulates Lung Adenocarcinoma Cell Proliferation and Invasion</td>
<td>Baohui Han</td>
<td>China</td>
</tr>
<tr>
<td>P1.04-047</td>
<td>The Inhibitory Effects of CDK4 and MDM2 on Migration and Invasion in Human Non-Small Cell Lung Cancer Cells</td>
<td>Soojeong Kang</td>
<td>USA</td>
</tr>
<tr>
<td>P1.04-048</td>
<td>DNA Demethylation Related Hypoxia-Induced Stem-Like Properties in Lung Cancer</td>
<td>ChanKwon Park</td>
<td>South Korea</td>
</tr>
<tr>
<td>P1.04-049</td>
<td>The MRE11/RAD50/NBS1 Complex Was Impaired in Lung Cancer from Chromate-Exposed Workers</td>
<td>Kazuya Kondo</td>
<td>Japan</td>
</tr>
<tr>
<td>P1.04-050</td>
<td>COX-2 Genetic Variants Influence Intratumoral Infiltration of Foxp-3-Positive Regulatory T Cells in Non-Small Cell Lung Cancer</td>
<td>Masao Nakata</td>
<td>Japan</td>
</tr>
<tr>
<td>P1.04-051</td>
<td>C. Elegans, an in Vivo Model for Lung Cancer: Effect of Chronic Exposure of Nicotine on Specific Mutants Relevant to Lung Cancer</td>
<td>Jacob J. Riehm</td>
<td>USA</td>
</tr>
<tr>
<td>P1.04-052</td>
<td>TGF-β Induced EMT and Stem-Like Characteristics in Lung Cancer</td>
<td>Seung Joon Kim</td>
<td>South Korea</td>
</tr>
<tr>
<td>P1.04-053</td>
<td>Characterization of Invasive Cancer Cells and Potential Therapeutic Effect of Suberoylanilide Hydroxamic Acid on Human Lung Cancer Metastasis</td>
<td>Shirong Zhang</td>
<td>China</td>
</tr>
<tr>
<td>Session</td>
<td>Title</td>
<td>Authors</td>
<td></td>
</tr>
<tr>
<td>---------</td>
<td>----------------------------------------------------------------------</td>
<td>--------------------------</td>
<td></td>
</tr>
<tr>
<td>P1.04-054</td>
<td>Mitochondrial Status in Peripheral Blood Mononuclear Cells in Relation to Cognitive Impairment in Lung Cancer Patients</td>
<td>Rodryg Ramlau, Poland</td>
<td></td>
</tr>
<tr>
<td>P1.04-055</td>
<td>Fibroblast-Dependent Cancer Cell Invasion: Analysis of Cancer-Associated Fibroblasts That Remodel the Extracellular Matrix</td>
<td>Shinya Neri, Japan</td>
<td></td>
</tr>
<tr>
<td>P1.04-056</td>
<td>Use of Pooled shRNA Synthetic Lethal Screens within an In Vivo Murine Model to Identify Microenvironment-Dependent Lung Cancer Genes</td>
<td>Nathaniel R. Little, USA</td>
<td></td>
</tr>
<tr>
<td>P1.04-057</td>
<td>Wnt Signaling Regulates Cancer Stem Cell in Lung Cancer SPC-A1 Cells</td>
<td>Baohui Han, China</td>
<td></td>
</tr>
<tr>
<td>P1.04-058</td>
<td>Inhibition of ERK1/2 Down-Regulates the Hippo/YAP Signaling Pathway in Human NSCLC Cells</td>
<td>David Jablons, USA</td>
<td></td>
</tr>
<tr>
<td>P1.04-059</td>
<td>The Role of Histone Methyltransferases G9a/Glp in Mouse Lung Tumor Propagating Cells and Lung Stem Cells</td>
<td>Samuel Rowbotham, USA</td>
<td></td>
</tr>
<tr>
<td>P1.04-060</td>
<td>Pathways Involved in Lung Adenocarcinomas, - Integrated Analyses on Methylation and mRNA Data</td>
<td>Vilde D. Haakensen, Norway</td>
<td></td>
</tr>
<tr>
<td>P1.04-061</td>
<td>Comparison of MET Expression in Primary and Corresponding Nodal and Distant Metastases in Non-Small Cell Lung Cancer (NSCLC)</td>
<td>Paul Mitchell, Australia</td>
<td></td>
</tr>
<tr>
<td>P1.04-062</td>
<td>Phagocytic Behaviour in Lung Adenocarcinoma Cells: Clinical Implications and Cellular Mechanisms</td>
<td>John Le Quesne, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>P1.04-063</td>
<td>Exposure to IL-1β Leads to EMT via Distinct Mechanisms in Acute and Chronic Inflammation in NSCLC</td>
<td>Rui Li, USA</td>
<td></td>
</tr>
<tr>
<td>P1.04-064</td>
<td>2'-Hydroxyflavanone Inhibits Lung Cancer Growth by Inhibiting Tumor Cell Proliferation and Angiogenesis</td>
<td>David Berz, USA</td>
<td></td>
</tr>
<tr>
<td>P1.04-065</td>
<td>Cyclin-Dependent kinase11 (CDK11) Is Crucial for Growth of Lung Cancer Cells</td>
<td>Tomohiko Kakumu, Japan</td>
<td></td>
</tr>
<tr>
<td>P1.04-066</td>
<td>Site-Selected Chromatin-Immunoprecipitation (ChIP) Analysis by Laser Captured Microdissection</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Shingo Sakashita, Japan

**P1.04-067:** Mitochondrial Respiration Capacity and Sensitivity to Glycolysis Blockade in Lung Cancer
Maya Ilouze, Israel

**P1.04-068:** Protein Tyrosine Kinase 7 Plays a TumorSuppressor Role by Inhibiting ERK and Akt Phosphorylation in Lung Cancer
Haewon Lee, South Korea

**P1.04-069:** LKB1 Inactivation Elicits a Redox Imbalance to Modulate Non-Small Cell Lung Cancer Plasticity and Therapeutic Response
Xiangkun Han, China

**P1.04-070:** Silencing of Rac3 Inhibits Proliferation and Induces Apoptosis of Human Lung Cancer Cells
Hongxu Liu, China

**P1.04-071:** Inhibition of EGFR Lysosomal Degradation in Lung Adenocarcinoma by Ubiquitin-Specific Protease 8 and Stratifin
Yun-Jung Kim, Japan

**P1.04-072:** Gene-Smoking Interactions in Lung Cancer Etiology
Christopher I. Amos, USA

**P1.04-073:** The Role of the Stress-Response to a Lung Cancer Diagnosis in Disease Progression
Hronn Hardardottir, Iceland

**P1.04-074:** ITPKA Expression in Lung and Other Cancers, Regulated via Gene Body Methylation, Functions as an Oncogene
Adi F. Gazdar, USA

**P1.04-075:** Kynurenine Pathway Activity in Peripheral Blood Mononuclear Cells and Cognitive Functions in Lung Cancer Patients
Rodryg Ramlau, Poland

**P1.04-076:** CDCA3 Is a Novel Cell Cycle Regulator in Lung Cancer
Kenneth J. O’Byrne, Australia

**P1.04-077:** KIF5B-RET Fusion Kinase Promotes Cell Invasion and Migration Which Can Be Suppressed by RET Inhibitors
Jianhua Chang, China

**P1.04-078:** Induction of Achaete-Scute Homologue 1 (ASCL1) by Cigarette Smoke Condensate in A549 Cells
Michael H. Lee, USA
P1.04-079: RBM5-Wnt/β-Catenin Signaling in Cigarette Smoke PM 2.5 Induced Alveolar Epithelial Injury and Its Molecular Mechanism
Zhang Jie, China

P1.04-080: miR-326 Is Down-Regulated in Non-Small Cell Lung Cancer and Targets NFIB, a Lung Developmental Gene: A Pilot Study
Deepali Jain, India

P1.04-081: Expression of PPAR-γ Ligand in Lung Cancer and Its Effect on the Apoptosis of Lung Cancer
Qiuping Luo, China

P1.04-082: Anti-Neoplastic Effects of 15(S)-HETE and 13(S)-HODE in Lung Cancer
George G. Chen, China

P1.04-083: The Metastasis-Related Noncoding RNA Expression Profile and LncRNA LOC101448202 Induces 95D Cell Migration and Tumor Growth
Shuanying Yang, China

P1.04-084: Ubiquitin Protein Ligase E3C Promotes Growth and Metastasis of Non-Small Cell Lung Cancer
Jie Gu, China

P1.04-085: The Role and Potential Mechanisms of LncRNA-TATDN1 in the Metastasis and Invasion of 95D Cell
Shuanying Yang, China

P1.04-086: Dopamine D2 Receptor Agonists Inhibit Lung Cancer Progression by Reducing Angiogenesis and Tumor Infiltrating Myeloid Derived Suppressor Cells
Luke H. Hoeppner, USA

P1.04-087: The Role and Mechanism of Twist1 in Non-Small Cell Lung Cancer Pathogenesis
Yong Song, China

P1.04-088: Lung Cancer Cells Can Alter the Behaviour of Normal Bronchial Epithelial Cells Through Multiple Mechanisms
Kenneth J O'Byrne, Australia

P1.04-089: MicroRNA miR-615-3p and let-7b Targets Multiple Key Pathways Overexpressed in Lung Adenocarcinoma
Oluf D. Røe, Norway

P1.04-090: Roles of MLF1IP in the Proliferation of Lung Adenocarcinoma Cells
Baohui Han, China

P1.04-091: Biological Significance of CHK2 Gene Expression in Lung Adenocarcinoma
Tatsuro Okamoto, Japan
P1.04-092: LKB1 Inactivation Confers Human Lung Adenocarcinoma with Strong Plasticity for Squamous Transdifferentiation
Xiangkun Han, China

P1.04-093: CCNY2 Promotes Lung Cancer Cell Migration and Invasion via Regulating F-Actin Expression
Wentao Yue, China

P1.04-094: NT5E(CD73) is a Target of miR-30a-5p and Plays a Critical Role in Non-Small Lung Cancer
Zeyi Liu, China

P1.04-095: Integrin α1β1 Regulates Cancer Stromal Stiffness and Promotes Tumorigenicity and Metastasis in Non-Small Cell Lung Cancer
Roya Navab, Canada

P1.04-096: Second Tumors in Lung Cancer (LC) Patients. Should We Think About This Issue in Long Term Survival Setting?
Norberto Olguin, Argentina

P1.04-097: Genome-Wide Methylome Alterations in Lung Cancer
Simon D. Spivack, USA

P1.04 BIOLOGY, PATHOLOGY, AND MOLECULAR TESTING – PRECLINICAL THERAPY

P1.04-098: Mithramycin Is a Potential Therapeutic Agent for Elimination of Stem-Like Cells in Lung Cancer
Haobin Chen, USA

P1.04-099: Wnt Blockers Inhibit the Proliferation of Lung Cancer Stem Cells
Baohui Han, China

P1.04-100: Combination of Pitavastatin and Erlotinib Induces Apoptosis and Growth Arrest in Non-Small Cell Lung Cancer (NSCLC)-Celllines
Christoph Minichsdorfer, Argentina

Hyun Chang, South Korea

P1.04-102: Ex Vivo 4D Lung Cancer Model CTCs Show Resistance to Chemotherapeutic Drugs
Dhruva K. Mishra, USA

P1.04-103: Oncolytic Virus Therapy for Lung Cancers Using a Genetically Engineered Oncolytic Herpes Simplex Virus Type 1 G47?
Yoshinori Sakata, Japan
P1.04-104: Lung Cancer Patients Derived Xenografts: Prospective Molecular Profiling and Potential Evaluation of Drug Resistance
Silvia Novello, Italy

P1.04-105: The Development and Assessment of Advanced Cellular Models for the Study of Non-Small Cell Lung Cancer
Anne-Marie Baird, Australia

P1.04-106: Granulocyte Colony-Stimulating Factor Enhances the Anticancer Effects of Cisplatin Against Lung Cancer by Promoting Angiogenesis
Yasushi Ohno, Japan

P1.04-107: Prediction of Molecular Tageting Drugs' Sensitivity Enabled by In-Vitro Drug Sensitivity Tests for Surgically Resected Lung Cancer
Ryohei Miyazaki, Japan

P1.04-108: Non-Invasive Assessment of Cisplatin and Erlotinib Efficacy in Lung Cancer by Monitoring an Orthotopic SCID Mouse Model with Computed Tomography
Tamaki Otani, Japan

P1.04-109: Antitumor Efficacy of Histone Deacetylase Inhibitor or in Combination with EGFR-TKI in Non-Small Cell Lung Cancer Cell Lines
Xiaohong Han, China

P1.04-110: Use of Blood Outgrowth Endothelial Cells as a Carrier of Oncolytic Vesicular Stomatitis Virus-Interferon Beta in Treating Metastatic NSCLC
Manish Patel, USA

P1.04-111: Establishing a Mouse Model for Radiation-Induced Esophagitis
Moon-June Cho, South Korea

P1.04-112: Rapamycin Attenuated Epithelial-Mesenchymal Transition in Lung Cancer Cells
Lianjun Lin, China

P1.04-113: Nonclinical Development of PF-06439535, a Potential Biosimilar to Bevacizumab
Julie A. Rosenberg, USA

P1.04-114: Effect of Interleukin-2 Treatment Combined with Magnetic Fluid Hyperthermia on Lewis Lung Cancer-Bearing Mice
Runlei Hu, China

P1.04-115: Chemotherapy and Targeted Therapy Sensitivity Testing in Malignant Pleural Effusions
Atila Akkoclu, Turkey
P1.04-116: The Role of JAK/STAT3 Signaling Pathway on Apoptosis of Lung Adenocarcinoma Cell Line PC-9 Induced by Icotinib
Shuanying Yang, China

P1.05 PREVENTION AND TOBACCO CONTROL

P1.05-001: Rural Tobacco Smoke Pollution: Preliminary Results of a Longitudinal Study
Kelly Buettner-Schmidt, USA

P1.05-002: Comparative Study regarding Perception of Japanese Tobacco-Related Disease Risk Warning Package Message
Tomoyasu Uno, Japan

P1.05-003: Dutch Government Taken to Court by 2 Chest Physicians Because of Violation WHO FCTC 5.3
Wanda de Kanter, Netherlands

P1.05-004: Smoking Prevention Intervention with School Classes at a University Hospital by Thoracic Surgeon and Pulmonologist
Sven Hillinger, Switzerland

P1.05-005: Italian Multicentric Survey on Smoking Cessation in Lung Disease Patients and the Role of Healthcare Workers in This Contest
Stefania Vallone, Italy

P1.05-006: One Cigarette Takes 12.6 Minutes of Your Life
Erik Thunnissen, Netherlands

P1.05-007: One-Stop Counselling, Social Support & Stop Smoking Aids Helps Smokers Quit
Emmanuel Odiase, Nigeria

P1.05-008: Big Tobacco and the Creation of an Epidemic of Smoking-Related Adenocarcinoma of the Lung: SEER-Based Analysis, 1973-2011
Gary Strauss, USA

P1.05-009: EGCG Regulated Ku70 Acetylation for Apoptosis in Human Lung Cancer A549 Cells
Min Li, China

P1.06 SCREENING AND EARLY DETECTION

P1.06 SCREENING AND EARLY DETECTION – CT SCREENING PROGRAMS AND IMAGING

P1.06-001: Ultra-Low Dose-CT Accurately Detects Significant Lung Nodules with a Fraction of the Radiation of Conventional Low Dose-CT
Alistair Miller, Australia
<table>
<thead>
<tr>
<th>P1.06-002:</th>
<th>Lung Cancer Screening Guidelines May Not Capture the Complete Population At-Risk</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>April Plank, USA</td>
</tr>
<tr>
<td>P1.06-003:</td>
<td>Low-Dose CT Lung Cancer Screening in the Community: A Prospective Cohort Study Incorporating a Gene-Based Lung Cancer Risk Test</td>
</tr>
<tr>
<td></td>
<td>Robert Young, New Zealand</td>
</tr>
<tr>
<td>P1.06-004:</td>
<td>Common Misconceptions About Lung Cancer Screening: A Nationwide Survey</td>
</tr>
<tr>
<td></td>
<td>Jean-François Morere, France</td>
</tr>
<tr>
<td>P1.06-005:</td>
<td>The Correlation between Visceral Pleura l Invasion in T1a Non-Small Lung Cancer and Lymph Node Metastasis</td>
</tr>
<tr>
<td></td>
<td>Mitsuhiro Tsuboi, Japan</td>
</tr>
</tbody>
</table>

**P1.06 SCREENING AND EARLY DETECTION – BIOMARKERS**

<table>
<thead>
<tr>
<th>P1.06-006:</th>
<th>Metabolomics by NMR Facilitates the Non-Invasive Diagnosis and Staging of NSCLC</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Clara Pérez-Rambla, Spain</td>
</tr>
<tr>
<td>P1.06-007:</td>
<td>Plasma Circulating MicroRNA-944 and MicroRNA-3662 as Novel Histologic Type-Specific Lung Cancer Biomarkers</td>
</tr>
<tr>
<td></td>
<td>Tomasz Powrózek, Poland</td>
</tr>
<tr>
<td>P1.06-008:</td>
<td>Functional Polymorphisms in PD-L1 Gene Are Associated with the Prognosis of Patients with Early Stage Non-Small Cell Lung Cancer</td>
</tr>
<tr>
<td></td>
<td>Deuk Kju Jung, South Korea</td>
</tr>
<tr>
<td>P1.06-009:</td>
<td>Volatolomic Signatures to Assess Sensitivity to FGFR Tyrosine Kinase Inhibitors</td>
</tr>
<tr>
<td></td>
<td>Regina Kwon, USA</td>
</tr>
<tr>
<td>P1.06-010:</td>
<td>Allelic Heterogeneity and Its Role in Identifying Non-Small Cell Lung Cancer Phenotypes</td>
</tr>
<tr>
<td></td>
<td>Lisa M. Alley, USA</td>
</tr>
<tr>
<td>P1.06-011:</td>
<td>miR-126 Is a Potential Diagnostic Marker for Malignant Pulmonary Nodules in Endobronchial Epithelial Lining Fluid</td>
</tr>
<tr>
<td></td>
<td>Nicolas Kahn, Germany</td>
</tr>
<tr>
<td>P1.06-012:</td>
<td>Components of Serum Peptidome Can Differentiate between Healthy Controls and Patients with Early Stage Lung Cancer</td>
</tr>
<tr>
<td></td>
<td>Piotr Widlak, Poland</td>
</tr>
</tbody>
</table>
P1.06-013: Delays of Diagnosis and Treatment of Lung Cancer in a Populous Region of Brazil  
Fernando C. Abrão, Brazil

P1.06-014: Impact of Surgery for Stage I Non-Small Cell Lung Cancer on Quality of Life  
Emanuela Taioli, USA

P1.06-015: A Population Based Study on Pulmonary Carcinoids in Iceland: Epidemiology, Diagnosis and Survival Over Sixty Years  
Astridur Petursdottir, Iceland

P1.06-016: A Novel Functional Polymorphism in CIR1 Gene Is Associated with the Risk of Lung Cancer  
Chengcheng Jin, South Korea

P1.06-017: Small Cell Lung Cancer in Lung Cancer Screening: Frequency and Outcome  
Stefano Sestini, Italy

P1.06-018: Can 30-Mortality after Lung Cancer Resection Be Used as an Individual Surgeon Quality Outcome Internationally? National Data from the UK  
Chiara Proli, United Kingdom

P1.06-019: A Comparison of Demographic Risk Variables for Lung Cancer in New Zealand Europeans and Maori: Are Maori More Susceptible to the Effects of Smoking?  
Raewyn J. Hopkins, New Zealand

P1.06-020: Detection of Aberrant ALK Expression from Circulating Tumor Cells for Accurate Monitoring of ALK Driven NSCLC  
Kasey D. Lawrence, USA

P1.06 SCREENING AND EARLY DETECTION – DIAGNOSTIC WORKUP

P1.06-021: Is Safe to Follow High-Risk Patients with Suspicious Lung Nodules without Invasive Tests?  
André Luiz C. Trajano, Brazil

David R. Baldwin, United Kingdom

P1.06-023: Addition of Low Dose Computed Tomography Image-Features Improves Diagnostic Accuracy for Indeterminate Pulmonary Nodules  
Roshni Bhagalia, USA

P1.06-024: Patterns of 18F FDG-PET/CT Studies in Patients with Suspected or Confirmed Lung Cancer - A Johannesburg Academic Hospital Perspective  
Olusegun A. Ayeni, South Africa
P1.06-025: Statistical Analysis of 18F-FDG-PET/CT Findings of Ground Glass Nodule (GGN)  
Kazuya Nishii, Japan

P1.06-026: 18F-FDG PET/CT Evaluation of Non-Small Cell Lung Cancer - Initial Experience from Johannesburg  
Osayande Evbuomwan, South Africa

P1.06 SCREENING AND EARLY DETECTION – PROGNOSTIC MARKERS

P1.06-027: Role of Brain MRI and PET-CT in Follow-Up after Lung Cancer Surgery  
Akira Sakurada, Japan

P1.06-028: Distribution of Stage, Surgical Methods and Prognosis of Lung Adenocarcinoma According to the Initial Diagnostic Patterns  
Hyo-Jun Jang, South Korea

P1.06-029: Serum Glutathione Peroxidase 3 as a Biomarker of Postoperative Relapse in Patients with Lung Cancer  
In-Jae Oh, South Korea

P1.07 SMALL CELL LUNG CANCER

P1.07 SMALL CELL LUNG CANCER - BIOLOGY

P1.07-001: Preoperative Serum proGRP as a Predictor for Lung Tumor Histology  
Marius Lund-Iversen, Norway

P1.07-002: FAK Inhibition by PF228 Has Anti-Tumoral Effects Associated with Inhibition of Histone 3 and Aurora Kinases A/B Phosphorylation in SCLC  
Sebahat Ocak, Belgium

P1.07-003: Role of Tumor Infiltrating Lymphocytes in Small Cell Lung Cancer  
Inderjit Mehmi, USA

P1.07 SMALL CELL LUNG CANCER – EXTENSIVE DISEASE

P1.07-004: Efficacy of Endostar Combined with Chemotherapy and Endostar Maintenance Treatment for Patients with Extensive Small-Cell Lung Cancer  
Li Chen, China

P1.07-005: Paclitaxel and Irinotecan in Platinum Refractory/Resistant Small Cell Lung Cancer: Final Analisis of One Galician Lung Cancer Group Experience  
Sergio Vzsquez-Estevez, Spain

P1.07-006: Final Results of Randomized Phase II Study of Carboplatin plus Irinotecan vs. Carboplatin plus Amrubin in ED-SCLC  
Yuka Fujita, Japan
P1.07-007: Prophylactic Cranial Irradiation in Extensive Stage Small Cell Lung Cancer: The Ottawa Hospital Experience
Andrew Bang, Canada

P1.07-008: Preliminary Results from a Phase Ib/II Trial of Belotecan plus Ifosfamide in Patients with Extensive-Stage Small-Cell Lung Cancer
Eun Kyung Cho, South Korea

P1.07 SMALL CELL LUNG CANCER – LIMITED DISEASE

P1.07-009: Effect of Accurate Heart Outlining on Cardiac Dose - the CONVERT Trial Experience
Corinne Faivre-Finn, United Kingdom

P1.07-010: Hyperfractionated Versus Hypofractionated Radiotherapy for Limited-Stage SCLC: A Retrospective Comparison of Two Prospective Studies
Ming Chen, China

P1.07-011: "Peripheral Limited" Small Cell Lung Cancer (SCLC). Does Surgical Resection Have a Role in Primary Management?
Mathew A. Vandeusen, USA

P1.07-012: Hypo- or Conventionally Fractionated Radiotherapy in Patients with Limited Stage Small Cell Lung Cancer (LS-SCLC): A Retrospective Analysis
Min Fan, China

P1.07 SMALL CELL LUNG CANCER – PROGNOSIS, EPIDEMIOLOGY AND OTHER

P1.07-013: Real-Life 2-Year Therapeutic Strategies in the Management of 525 Small-Cell Lung Cancers: The ESCAP Study Preliminary Results
Didier Debieuvre, France

P1.07-014: Predictors of Survival in Small Cell Lung Cancer (SCLC) Patients (pts) < 50 Years of Age: Results from the California Cancer Registry (CCR)
Joshua D. Lara, USA

P1.07-015: The Prognostic Value of the Neutrophil Lymphocyte Ratio in Patients with Small Cell Lung Cancer
Harjot Kaur, USA

P1.07-016: Comparison of PET/CT, 99mTc-MDP Bone Scan and Serum Alkaline Phosphatase for Detecting Bony Metastasis in Patients with Small Cell Lung Cancer
Min Fan, China

P1.08 THYMOMA, MESOTHELIOMA AND OTHER THORACIC MALIGNANCIES

P1.08 THYMOMA, MESOTHELIOMA AND OTHER THORACIC MALIGNANCIES - MESOTHELIOMA
P1.08-001: **Rituximab for Treatment of Lymphoma Induced Marked Regression of Malignant Mesothelioma with Dynamic Changes of Serum Cytokine Profiles**
Keisuke Aoe, Japan

P1.08-002: **Stat3 Is a Potential Target for Malignant Pleural Mesothelioma (MPM) Treatment**
Seiji Matsumoto, Japan

P1.08-003: **Minimal Asbestos Exposure in Germline BAP1 Heterozygous Mice Is Associated with Deregulated Inflammatory Response and Increased Risk of MM**
Andrea Napolitano, USA

P1.08-004: **Aki1 as a Potential Therapeutics Target in CREB1 Signaling in Malignant Mesothelioma**
Tadaaki Yamada, USA

P1.08-005: **Met and PI3K/mTOR as a Potential Combinatorial Therapeutic Target in Malignant Pleural Mesothelioma**
Rajani Kanteti, USA

P1.08-006: **Lung Toxicity after Post-Operative Radiotherapy after EPP for Mesothelioma and Pneumonectomy for Non-Small Cell Lung Cancer**
Dirk De Ruysscher, Belgium

P1.08-007: **Programmed Cell Death 1 Ligand 1 (PD-L1) Expression in Thymoma**
Shintaro Yokoyama, Japan

P1.08-008: **Efficacy of Palliative Chemotherapy in Malignant Pleural Mesothelioma from Spanish BEMME Database. The Spanish Lung Cancer Group (SLCG)**
Jordi Remon, Spain

P1.08-009: **Hepatocyte Growth Factor (HGF) Expression in Malignant Mesothelioma: A Potential Predictive Marker for met/HGF-Targeted Therapy?**
Peter B. Illei, USA

P1.08-010: **Understanding the Genetic Landscape of Malignant Mesothelioma - A Comparison of Human and Murine Mesothelioma Cell Lines**
Jenette Creaney, Australia

P1.08-011: **Clinical Outcome and Prognostic Factors for Advanced Malignant Mesothelioma (MM) Patients (pts) Treated on Phase I Trials**
Timothy A. Yap, United Kingdom

P1.08-012: **Immunohistochemistry as Prognostic Markers for Malignant Pleural Mesothelioma**
Taiichiro Otsuki, Japan
P1.08-013: Long Non-Coding RNAs Associated with Lysine Demethylases Are Overexpressed and Epigenetically Regulated in Malignant Pleural Mesothelioma
Steven G. Gray, Ireland

P1.08-014: The Small Molecule Inhibitor, LCRF004, Is Effective in Targeting the RON/MST1R Pathway in Malignant Pleural Mesothelioma
Anne-Marie Baird, Australia

P1.08-015: Malignant Pleural Mesothelioma: Observational and Retrospective Analysis of Spanish Database (BEMME). The Spanish Lung Cancer Group (SLCG)
Noemi Reguart, Spain

P1.08-016: Ponatinib Shows Promise in Malignant Pleural Mesothelioma Cells with Abl Pathway Dysregulation
Hassan Lemjabbar-Alaoui, USA

P1.08-017: microRNAs Expression in Malignant Pleural Mesothelioma, Asbestosis and Benign Pulmonary Disease
Luca Ampollini, Italy

P1.08-018: Spontaneous Regression of Mesothelioma
Gunnar N. Hillerdal, Sweden

P1.08 THYMOMA, MESOTHELIOMA AND OTHER THORACIC MALIGNANCIES – OTHER THORACIC MALIGNANCIES

P1.08-019: Pure Bronchoplasty without Lung Parenchyma Resection for Central Carcinoid
Oleg Pikin, Russia

P1.08-020: Survival Impact of Adjuvant Radiation and Chemotherapy in Patients with Typical and Atypical Pulmonary Carcinoids
Lindsay M. Hannan, USA

P1.08-021: Role of Surgery in Sarcomatoid Tumors of the Lung: A Multicentre Analysis
Tommaso Ricchetti, Italy

P1.08-022: Intraoperative Brachytherapy for Thoracic Malignancies Resected with Close or Positive Margins
Andreas Rimner, USA

P1.08-023: Induction Chemotherapy Increases the Survival of Patients with Primary Neuroectodermal Tumors of the Thorax
Akif Turna, Turkey

P1.08-024: Large Cell Neuroendocrine Carcinoma: How Accurate Are the WHO 2004 Classification Criteria Applied?
Jules L. Derks, Netherlands

**P1.08-025:** Tumor Control of Advanced Pulmonary Neuroendocrine Tumors (Carcinoids) with Somatostatin Analogs: Experience at Gustave Roussy
Ivana Sullivan, France

**P1.08-026:** First Case of SMARCB1(INI1)-Deficient Squamous Cell Carcinoma of the Pleura
Kazushi Yoshida, Japan

**P1.08-027:** Clinicopathologic Study and Prognostic Analysis of Bronchial Mucoepidermoid Carcinoma
Jian Ni, China

**P1.08-028:** PD-L1 Expression in Neuroendocrine Tumors of the Lung
Kenjiro Tsuruoka, Japan

**P1.08-029:** Combination Treatment of Intrathoracic Esophageal Cancer
Olga Lebedieva, Ukraine

**P1.08-030:** Increasing the Interval between Neoadjuvant Chemoradiotherapy and Surgery in Esophageal Cancer. A Meta-Analysis of Published Studies
Yaping Xu, China

**P1.08-031:** Induction of Protein Citrullination and Auto-Antibodies Production in Murine Exposed to Nickel Nanomaterials
Steven G. Gray, Ireland

**P1.08-032:** Primary Pulmonary Lymphoma: Clinical Analysis of 34 Cases
Narjust Duma, USA

**P1.08 THYMOMA, MESOTHELIOMA AND OTHER THORACIC MALIGNANCIES - THYMOMA**

**P1.08-033:** pRb and p16INK4 in Human Thymic Epithelial Tumors in Relation to Human Polyomavirus 7
Jos Maessen, Netherlands

**P1.08-034:** The Clinicopathological Significance of PD-L1 Expression in Thymoma
Yohei Takumi, Japan

**P1.08-035:** Pan-European Survey on Thymic Malignancies: A Collaboration of the EORTC Lung Cancer Group (LCG) with the RYTHMIC Network
Jessica Menis, Belgium

**P1.08-036:** Long-Term Survival after Surgical Treatment for Thymic Carcinoma
Hao Fu, China

**P1.08-037:** PD-L1 Expression in Surgically Resected Thymic Epithelial Tumor
Myung-Ju Ahn, South Korea
### P1.08: The Effect of the WHO Histologic Classification on Thymic Specific Survival and Overall Survival

Karl Uy, USA

### P1.08: Adjuvant Treatment of Thymic Carcinoma

Yen-Han Tseng, Taiwan

---

### P1.10: Advocacy

### P1.10-001: EGFR Mutation Testing Patterns and Results in Brazil and the Need for Greater Public Health Awareness of Molecular Testing

Gilberto De Lima Lopes, Brazil

### P1.10-002: Lung Cancer Patients’ Perspectives on Multi-Disciplinary Care in a Community Setting

Orion Osborne, USA

### P1.10-003: Lung Cancer in Ireland 2010 - 2015 - Are We Making Progress?

Aoife McNamara, Ireland

### P1.10-004: Novel Survey to Identify Single Greatest Challenge for Lung Cancer Patients and Carers

Aoife McNamara, Ireland

### P1.10-005: Immunotherapy, What Lung Cancer and Melanoma Patients ...and Physicians, Know

Silvia Novello, Italy

### P1.10-006: Defining a Standard Set of Patient-Centered Outcomes for Patients with Lung Cancer

Jan P. Van Meerbeeck, Belgium

### P1.10-007: Impact of Intensive Interprofessional Perioperative Management on Clinical Outcome in the Elderly Patients with Lung Cancer Surgery

Hidejiro Torigoe, Japan & Marko Jakopovic, Croatia

---

### P1.11: Palliative and Supportive Care

### P1.11-001: Short Form Chronic Respiratory Questionnaire Validation in a Lung Cancer Population

Alex Molasiotis, Hong Kong

### P1.11-002: The Impact of Gastric Acid Suppressing Therapy on Treatment Outcomes of EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

Nesaretnam B. Kumarakulasinghe, Singapore
Monday, September 7, 2015

P1.11-003: New Clinical and Biologic Insight Into Lung Cancer-Associated Cachexia From a Large Cohort Study
Puneeth Iyengar, USA

P1.11-004: Impact of Lung Cancer Surgery on Quality of Life of Family Caregivers
Dan J. Raz, USA

P1.11-005: Enhancing Evaluation of Cancer Cachexia in Patients with NSCLC by Assessing Change in Skeletal Muscle Mass at the L1 Level on Routine Chest CT
Jose N. Galeas, USA

P1.11-006: Association between Nutritional Status Variables and Fatigue Diagnosis in Patients with Non Small Cells Lung Cancer
Martha De La Torre-Vallejo, Mexico

P1.11-007: To Determine Whether Psychosocial Factors Predict Depression among Older Indian Lung Cancer Patients
Gouri Shankar Bhattacharyya, India

P1.11-008: What Happens to the Pleural Space Affected by Malignant Effusion after Bedside Pleurodesis?
Ricardo M. Terra, Brazil

P1.11-009: Predictors of Hospital Discharge in Cancer Patients with Pericardial Effusion Who Undergo Surgical Pericardial Drainage
Ricardo M. Terra, Brazil

P1.11-010: Therapeutic and Supportive Care Unmet Needs in Lung Cancer Patients
Ronak Savla, USA

P1.11-011: Taste Disorder in Patients with Thoracic Malignancy Who Received Chemotherapy
Keisuke Azuma, Japan

P1.11-012: Process for Developing a Rapid Tissue Donation Program in a Thoracic Program: Ethical and Logistical Considerations
Matthew B. Schabath, USA

P1.11-013: Place and Cause of Death in Patients with Lung Cancer in the United Kingdom
Emma L. O'Dowd, United Kingdom

P1.12 COMMUNITY PRACTICE

P1.12-001: Trends in Accuracy and Comprehensiveness of Pathology Reports of Resected Non-Small Cell Lung Cancer (NSCLC) in a High Mortality Area of the US
Matthew P. Smeltzer, USA

P1.12-002: International Online Tool for Therapeutic Decision Making in NSCLC (V2.0)
David R. Gandara, USA

**P1.12-003:** Acquisition of and Early Clinical Results of Electromagnetic Navigational Bronchoscopy for Diagnosis of Lung Cancer in a Community Setting  
Royce Calhoun, USA

**P1.12-004:** Early Results of Endobronchial Ultrasound for Lung Cancer Mediastinal Nodal Staging in a Community Setting  
Royce Calhoun, USA

**P1.12-005:** Concomitant Electromagnetic Navigational Bronchoscopy and Endobronchial Ultrasound to Diagnose and Stage Lung Cancer in a Community Setting  
Royce Calhoun, USA

**P1.12-006:** Factors That Influence Tobacco Consumption Among Portuguese Adolescents  
Henrique Queiroga, Portugal

**P1.12-007:** Thoracic Surgery Information on the Internet: Multilingual Quality Assessment  
Stephen Barnett, Australia

**P1.12-008:** Components of Creating and Implementing a Comprehensive Lung Cancer Program in a Community Setting  
Royce Calhoun, USA

**P1.12-009:** Lung Cancer in Octogenarians  
Ana Laura Ortega Granados, Spain

**P1.12-010:** Bench to Bedside Detection of Actionable Genotypes by SNaPshot for Lung Cancer Panel  
Anuradha Choughule, India

**P1.12-011:** Treatment Patterns and Overall Survival for Advanced NSCLC Following Platinum-Based Chemotherapy in US Community Oncology Clinical Practice  
Caroline McKay, USA